US › Healthcare

Adagene Inc (ADAG)

US · Healthcare · Biotechnology

$3.37+6.31%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.6M

Net profit

$-16.4M

EPS

$0.00

EPS estimate

$-0.21

Net margin

-1,011.1%

EPS came in at 0.00 against a street estimate of -0.21 — a beat of 100.0%.

Key statistics

Market cap

$228.3M

Forward P/E

0.0

P/B

2.48

Book value

$1.33

EPS (TTM)

$-0.39

52-week high

$4.85

52-week low

$1.30

50-day MA

$3.78

200-day MA

$3.25

Beta

0.56

Analyst view

Analysts rate Adagene Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $10.09.

Shareholding

Insiders

11.36%

Institutions

35.94%

Largest institutional holders

Fund	Stake
HSG Holding Ltd	2.00%
Squadron Capital Management LLC	1.86%
Ameriprise Financial Inc	0.91%
Exome Asset Management LLC	0.73%
Mill Creek Capital Advisors LLC	0.30%
Quadrature Capital Limited	0.12%
Morgan Stanley - Brokerage Accounts	0.10%
Amvescap Plc.	0.07%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Adagene Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.